Such improved oncological outcomes have raised questions regarding the optimal role of radiation therapy (RT), more specifically regional nodal irradiation (RNI), in HER2 + BC, particularly in patients who achieve pCR following primary systemic therapy (PST). This evidence concerns the gene ERBB2 and breast cancer.